

Biomarkers: Discovery Techniques and Applications – A Global Market Overview

"The report reviews, analyzes and projects the global market for Biomarkers for the period 2016-2025. The Biomarker Discovery Technologies market analyzed in this report constitutes Omics Technologies, Bioimaging, and Bioinformatics. Market for Biomarkers Applications analyzed in this study comprises Oncology, Cardiology, Neurology and Other Applications (includes Immunological Disorders, Infectious Diseases, Gastrointestinal Ailments etc.)."

Published: August 2019

Report Code: BT006

Pages: 410


Charts: 149

Price: \$4500 Single User License, \$7200 Enterprise License

Report Synopsis

The factors driving the Biomarkers market growth includes elevated demand for personalized medicine, technological advancement, immense utilization of biomarkers in drug discovery and development procedures, massive research on biomarkers, increasing awareness about role of biomarkers in early disease diagnosis, increase research funding, and many more.

Global market for Biomarkers is dominated by Oncology, in terms of application, estimated at a market share of 41.2% in 2018 and forecast to touch US\$15.6 billion in 2019. The overall market for Biomarkers is projected to reach approximately US\$50 billion by 2021.



Research Findings & Coverage

- Worldwide market for Biomarkers is analyzed in this report with respect to discovery technologies and therapeutic areas/applications
- Biomarkers' market size is reported in this study by biomarker discovery technologies, therapeutic/applications areas across all major countries
- Biomarkers Detection by Glycan Antibody Technique
- Role of Proteomic Techniques in Discovering Gingival Crevicular Fluid Biomarkers

- Combination of sTRA and CA19-9 Test to Detect Pancreatic Cancer Biomarkers
- Discovery of Novel Imaging Biomarker for Coronary Inflammation
- Key business trends focusing on product innovations/developments, M&As, JVs and other recent industry developments
- Major companies profiled – 51
- The industry guide includes the contact details for 225 companies

Product Outline

The report analyzes the market for the following key discovery technologies of Biomarkers:

- Omics Technologies
 - Proteomics
 - Genomics
 - Metabolomics
 - Other
- Bioimaging
 - MRI
 - CT
 - Ultrasound
 - Other
- Bioinformatics

The market for major applications of Biomarkers explored in this report comprise the following:

- Oncology
- Cardiology
- Neurology
- Other

Analysis Period, Units and Growth Rates

- The report reviews, analyzes and projects the global Biomarkers market for the period 2016-2025 in terms of market value in US\$ and the compound annual growth rates (CAGRs) projected from 2018 through 2025

Geographic Coverage

- North America** (United States, Canada and Mexico)
- Europe** (Germany, United Kingdom, France, Italy, Spain, Sweden and Rest of Europe)
- Asia-Pacific** (China, Japan, India, Australia and Rest of Asia-Pacific)
- Rest of World**

SAMPLE COMPANY PROFILE

ABBOTT DIAGNOSTICS (UNITED STATES)

A Division of Abbott Laboratories, 675 N. Field Drive
 Lake Forest, Illinois 60045
 Phone: 224-667-6100
 Website: www.diagnostics.abbott

Business Profile

Established in Illinois, United States, Abbott Diagnostics, a division of Abbott Laboratories, is a global provider of diagnostic solutions. The company is engaged in offering medical diagnostic instruments, tests, automation and informatics solutions for hospitals, reference labs, blood centers, emergency departments, physician offices and clinics. The company offers a range of personalized solutions via clinical chemistry, coagulation, hematology, immunoassay, transfusion medicine, point of care, informatics and molecular diagnostics products. The molecular diagnostics business unit is engaged in developing premier biomarkers to accelerate oncology product portfolio.

Business Analysis

Business Area	Operation Particulars
Core Laboratory	Offers solutions comprising automation, clinical chemistry, coagulation, hematology, immunoassay, integrated systems, and professional services and informatics; as well as personalized solutions comprising Alinity c (clinical chemistry), Alinity i (immunoassay), Alinity hs and Alinity hq (hematology), and Alinity PRO (informatics)
Molecular	Manufactures and markets molecular diagnostic solutions comprising assays and solutions such as AneuVysion, IntelliFISH, PathVysion, UroVysion and RealTime assays; FISH and RealTime PCR automation systems for increasing laboratory efficiency and consistency; assays for detecting and monitoring diseases, such as HIV, HCV, HBV, CT/NG; innovative FISH assays to diagnose hematology, breast, lung, bladder and other solid tumors; and a broad range of FISH probes for preimplantation, prenatal and postnatal genetic testing research; and Alinity m personalized molecular solution Offers first gene-based test designed for detecting HER-2 gene found in many breast cancer patients; first CE marked dried blood spot test for HIV early infant diagnosis; and first FDA approved test for identification of ALK gene rearrangements
Point of Care	Offers i-STAT system products and services such as i-STAT handheld blood analyzer, i-STAT test cartridges, i-STAT data management software, i-STAT AQF, INFO HQ MANAGER, and STATNotes; and i-STAT Alinity system
Transfusion Medicine	Offers innovative instruments, assays, informatics and automation solutions comprising PRISMnEXT process automation system, PRISM Director, ACCELERATOR a3600 automated system, ARCHITECT immunoassay systems, AlinIQ suite of professional services, and Alinity s personalized solution for blood and plasma screening


.....more

SAMPLE TABLE/CHART

Glance at 2019 Global Biomarkers Market Share (%) by Geographic Region - North America, Europe, Asia-Pacific and Rest of World



North American Biomarkers Market Analysis (2016-2025) by Discovery Technology - Omics Technologies, Bioimaging and Bioinformatics in USD Million



KEY PLAYERS PROFILED

- Abbott Diagnostics
- Agilent Technologies, Inc.
- Beckman Coulter, Inc.
- Biocartis NV
- bioMérieux SA
- Bio-Rad Laboratories, Inc.
- Bruker Corporation
- Caprion Biosciences, Inc.
- Charles River Laboratories, Inc.
- EKF Diagnostics Holdings Plc
- F. Hoffmann-La Roche AG
- GE Healthcare
- Genedata AG
- Genomic Health, Inc.
- Human Metabolome Technologies
- Illumina, Inc.
- Koninklijke Philips N.V
- Meso Scale Diagnostics LLC.
- Metabolon, Inc.
- MilliporeSigma
- Myriad Genetics, Inc.
- NanoString Technologies, Inc.
- PerkinElmer, Inc.
- QIAGEN B.V.
- Siemens Healthineers
- Singulex, Inc.
- Thermo Fisher Scientific, Inc.
- Waters Corporation

.....more

TABLE OF CONTENTS

PART A: GLOBAL MARKET PERSPECTIVE 1

1. INTRODUCTION	1
1.1 Product Outline.....	4
1.1.1 Biomarkers Defined	4
1.1.2 Biomarkers in Medicine	4
1.1.2.1 A History of Biomarkers	5
1.1.2.1.1 Philadelphia Chromosome	5
1.1.2.1.2 HIV Viral Load	5
1.1.2.1.3 HER-2 Gene and Receptor.....	6
1.1.2.2 Biomarkers for Diseases and Biomarkers for Drugs	6
1.1.2.3 Prerequisites of Biomarkers.....	8
1.1.2.4 Categorization of Biomarkers	9
1.1.2.4.1 Categorization of Biomarkers based on Types	9
1.1.2.5 Biomarkers in Drug Development	9
1.1.2.6 Biomarkers in Diseases	11
1.1.3 Biomarkers Discovery Technologies.....	13
1.1.3.1 Omics Technologies	13
1.1.3.1.1 Proteomic Methods of Biomarkers Discovery ...	13
1.1.3.1.1.1 2D-PAGE (Two-Dimensional Gel Electrophoresis).....	13
1.1.3.1.1.2 LC-MS (Liquid Chromatography Mass Spectrometer)	14
1.1.3.1.1.3 SELDI-TOF (Surface-Enhanced Laser Desorption/Ionization)	15
1.1.3.1.1.4 Immunohistochemistry	15
1.1.3.1.1.5 Antibody (Ab) Microarray	16
1.1.3.1.1.6 Tissue Microarray	16
1.1.3.1.2 Genomic Methods of Biomarkers Discovery...	16
1.1.3.1.2.1 Northern Blot.....	17
1.1.3.1.2.2 Polymerase Chain Reaction (PCR)	18
1.1.3.1.2.2.1 Real Time PCR	18
1.1.3.1.2.3 Gene Expression	18
1.1.3.1.2.4 Serial Analysis of Gene Expression (SAGE) ...	19
1.1.3.1.2.5 DNA Microarray	20
1.1.3.1.3 Metabolomics Methods of Biomarkers Discovery	21
1.1.3.1.4 Other Omics Technologies for Biomarkers Discovery	21
1.1.3.1.4.1 Lipidomics	21
1.1.3.1.4.2 Glycomics.....	22
1.1.3.1.4.3 Secretomics	22
1.1.3.1.4.3.1 Application of Secretomics in Discovery of Cancer Biomarkers	23
1.1.3.1.4.3.2 Application of Secretomics in Assisted Reproductive Technologies.....	24
1.1.3.2 Imaging Technologies	24
1.1.3.2.1 Magnetic Resonance Imaging (MRI)	25
1.1.3.2.2 Computed Tomography (CT).....	25
1.1.3.2.3 Ultrasound (US)	25
1.1.3.2.4 X-Rays	25
1.1.3.2.5 Positron Emission Tomography (PET)	26
1.1.3.2.6 Single Photon Emission Computed Tomography (SPECT)	26
1.1.3.2.7 Others	26
1.1.3.3 Bioinformatics.....	26
1.1.4 Therapeutic Areas for Biomarkers	28
1.1.4.1 Cancer Biomarkers	28
1.1.4.1.1 Cancer Biomarkers Defined	28
1.1.4.1.2 Functions of Biomarkers in Cancer Medicine. .	28
1.1.4.1.2.1 Evaluation of Risk	28
1.1.4.1.2.2 Diagnosis.....	29
1.1.4.1.2.3 Prognosis and Prediction of Therapy	29
1.1.4.1.2.4 Pharmacodynamics and Pharmacokinetics....	29
1.1.4.1.2.5 Therapy Response Monitoring.....	30

1.1.4.1.2.6 Predicting or Monitoring Recurrence of Cancer.....	30
1.1.4.1.3 Functions of Biomarkers in Cancer Research ..	31
1.1.4.1.3.1 Drug Target Discovery and Development	31
1.1.4.1.3.2 Surrogate Endpoints	31
1.1.4.1.4 Categories of Cancer Markers.....	32
1.1.4.2 Cardiac Biomarkers	33
1.1.4.2.1 Measurement Applications of Cardiac Biomarkers	33
1.1.4.2.2 Classes of Cardiac Marker Tests	33
1.1.4.2.2.1 Shortcomings of Cardiac Marker Tests ...	34
1.1.4.2.3 Biomarkers of Coronary Artery Disease	34
1.1.4.2.4 Role Played by Innovative Multiple Biomarkers in Predicting Cardiovascular Outcomes	35
1.1.4.3 Biomarkers for Neurological Disorders.....	36
1.1.4.4 Other Therapeutic Areas for Biomarkers	37
1.1.4.4.1 Biomarkers of Diabetes.....	37
1.1.4.4.2 Biomarkers of Aging.....	38
2. KEY MARKET TRENDS	39
2.1 Biomarkers Detection by Glycan Antibody Technique	39
2.2 Role of Proteomic Techniques in Discovering Gingival Crevicular Fluid Biomarkers	39
2.3 Novel Biomarkers May Assist Rapid Diagnosis of Autism	40
2.4 Detection of Autoimmune and Inflammatory Disorders Using Aberrant Non-Coding RNA	40
2.5 Abnormal miRNA Expression Profiles of T Cells Acts as Biomarkers of Pathogenesis and Ailment in SLE Sufferers	41
2.6 Combination of sTRA and CA19-9 Test to Detect Pancreatic Cancer Biomarkers	41
2.7 Proteomics Application to Discover Serum Biomarkers of Kawasaki Disease.....	41
2.8 Novel Rheumatoid Arthritis Biomarkers Detected by Researchers	42
2.9 Discovery of New Kidney Cancer Biomarkers	42
2.10 Correlation of Novel Inflammatory Biomarkers with Elevated Thrombosis Risk in Cancer Survivors ..	42
2.11 Identification of Biomarker for Widespread Heart Failure Type	43
2.12 Discovery of Novel Imaging Biomarker for Coronary Inflammation.....	43
2.13 A Novel Biomarker Based Bioimaging Approach for Kidney Cancer Cell Assessment	44
2.14 New Biomarker and Therapy for Melanoma has Been Discovered by BU Investigators	44
2.15 microRNA Signature – A Novel Biomarker Discovered for Postoperative Liver Disorder	45
3. KEY GLOBAL PLAYERS	46
Abbott Diagnostics (United States)	46
Agendia NV (The Netherlands).....	49
Agilent Technologies, Inc. (United States).....	50
Asuragen, Inc. (United States).....	59
Beckman Coulter, Inc. (United States).....	61
Biocartis NV (Belgium)	64
bioMérieux SA (France).....	66
Bio-Rad Laboratories, Inc. (United States).....	67
Bruker Corporation (United States).....	70
Caprion Biosciences, Inc. (Canada)	72
Charles River Laboratories, Inc. (United States)	74
Cisbio Bioassays (France).....	76
EKF Diagnostics Holdings Plc (United Kingdom)	78
Enzo Biochem, Inc. (United States)	81
Epigenomics AG (Germany)	82
F. Hoffmann-La Roche AG (Switzerland)	83

GE Healthcare (United States)	86
Genedata AG (Switzerland)	88
Genomic Health, Inc. (United States).....	89
Human Metabolome Technologies (Japan)	90
illumina, Inc. (United States)	91
Janssen Pharmaceutica NV (Belgium)	99
Koninklijke Philips N.V. (The Netherlands).....	100
Meso Scale Diagnostics LLC. (United States).....	101
Metabolon, Inc. (United States).....	103
MilliporeSigma (United States).....	104
Myriad Genetics, Inc. (United States)	106
NanoString Technologies, Inc. (United States).....	108
Nexus Dx (United States)	111
PerkinElmer, Inc. (United States)	112
Pharmaceutical Product Development LLC (United States)	114
QIAGEN B.V. (The Netherlands).....	115
Rosetta Genomics (Israel).....	118
Siemens Healthineers (Germany)	119
Singulex, Inc. (United States)	123
Thermo Fisher Scientific, Inc. (United States)	124
Waters Corporation (United States)	126
4. KEY BUSINESS AND PRODUCT TRENDS	128
therascreen® PIK3CA RQO PCR Kit, the First FDA-Cleared Companion Diagnostic Assay to detect 11 PIK3CA Gene Mutations.....	128
Establishment of APIS Assay Technologies Ltd. for Broadening Biomarker Research in Europe	128
Siemens Releases a Novel Atellica CH Enzymatic Hemoglobin A1c (A1c_E) Assay for Diabetes	128
Development of New Ultra-High Field 18 Tesla MRI System by Bruker and Champalimaud	128
Development of Diagnostic Tool for Molecular Biomarker Detection by GE and Indi Molecular	129
Epigenomics' Application for Colorectal Cancer Screening Blood Test Accepted by Centers for Medicare & Medicaid Services for NCD review	129
Seramatrix Corporation Acquired by Caprion Biosciences...	129
US FDA Offers 510 (k) Clearance for Beckman Coulter's Early Sepsis Indicator	129
Agendia's New Innovation and R&D Excellence Center in the Netherlands.....	130
Abbott'sCore Laboratory Instruments to Employ Banyan's Traumatic Brain Injury Blood Biomarkers	130
Expansion of Bruker's MALDI Biotyper, IR Biotyper and Fluorocycler XT Product Portfolio	130
Cisbio Bioassays Acquired by PerkinElmer	130
Bio-Rad's IH-500 Blood Typing and Screening System Receives U.S. FDA Clearance.....	131
NanoString and Leica Biosystems Ink Deal to Market Products for High Throughput Spatial Analysis	131
New Immunoassay for Kratom Alkaloid Mitragynine Screening Introduced by Thermo Fisher Scientific.....	131
Bio-Techne and NanoString in Collaboration to Develop Integrated Workflow for RNA Spatial Profiling	131
Myriad Introduces Prequel™ Prenatal Screen with all 23 Chromosome Pairs	132
Caprion Biosciences Advances Biomarker Discovery and Immune Monitoring by Providing Mass Cytometry Services.....	132
EKF Diagnostics Inks Pact with McKesson to Distribute DiaSpect Tm Hemoglobin Analyzer in the United States	132
Grant of European Patent for Singulex High Sensitivity Methods to Quantify Cardiac Troponin	133
Genomic Health Develops IVD Version of Idylla™Oncotype DX® GPS™ Test	133
Epigenomics Initiates Prospective Clinical Study for Liver Cancer Detection DNA Biomarkers	133
Pacific Biosciences to be Taken Over by Illumina to Speed- Up Scientific Discovery	133
bioMérieux Reinforces its Immunoassay Offerings by Acquiring Major Shares in Hybiome	134
BIOFIRE® FILMARRAY® Pneumonia Panels of bioMérieux Receives CE Mark and FDA Clearance.....	134
Siemens Introduces Magnetom Lumina (3 Tesla) and Magnetom Altea MRI Systems	134

USDA Contract Awarded for Bio-Rad® Pathogen Detection Testing Products 134

Epigenomics AG Receives CE Mark for Liquid Biopsy Test for Liver Cancer Detection 135

Myriad and Pfizer Inks Deal to Commercialize Myriad's BRACAnalysis CDx® as a Companion Diagnostic with Pfizer's Talazoparib 135

Healthy.io Join Forces with Siemens to Enhance Kidney Disease Monitorization 135

Introduction of TruSight Oncology 500 by Illumina for Pan Cancer Tumor Profiling 136

Setting up of High-field 9.4 Tesla Preclinical PET/MR System at German Cancer Research Center by Bruker .. 136

US Department of Defense Awards Contract to Procure Banyan Brain Trauma Indicator 136

Commercial Launch of Singulex Clarity C. diff Toxin A/B Assay 136

Agendia in Collaboration with Genecast Offers MammaPrint® and BluePrint® Tests in China for the First Time 137

Release of New Preclinical PET/CT Si78 Scanner by Bruker .. 137

Primity Bio Acquired by Caprion Biosciences 137

Three Low Cost Cancer Detecting Biomarkers from ENZO Biochem Successfully Validated 138

Launch of Shimadzu Q-TOF LCMS-9030 Mass Spectrometer 138

Introduction of Novel SKYSCAN 2214 Ultra-High Resolution Nano-CT by Bruker 138

Launch of ParaVision® 360 and AVANCE® NEO Systems by Bruker 139

NanoString Collaborated with National Cancer Institute to Improve Cancer Immunotherapy Biomarker Discovery .. 139

Thermo Fisher Scientific Opens Precision Medicine Science Center in The United States 139

MyriadGenetics to Acquire Counsyl 140

Thermo Fisher Scientific Inks Deal with Daiichi Sankyo and Takeda Pharmaceuticals to Expand Oncomine Dx Target Test 140

sphingotec to Offer penKid® and bio-ADM® Biomarkers on NEXUS IB 10 POC Testing Platform 140

Unicancer Chooses Agendia's MammaPrint® and BluePrint® Tests 141

Bio-Rad Introduces Bio-Plex Pro human Cytokine Screening Panel 141

EKF Wins FDA Clearance for DiaSpect Tm Hemoglobin Analyzer 141

Myriad's BRACAnalysis® Diagnostic System Receives Pre-Market Approval in Japan 142

NanoString to Market Digital Spatial Profiling Service through Leading Contract Research Organizations 142

NanoString Launches Breast Cancer 360 Research Panel 142

Shimadzu Launches UV-1900 UV-VIS Spectrophotometer ... 142

Agreement Signed by Illumina and Loxo to Co Develop NGS Based Pan Cancer Companion Diagnostics 143

Strengthening of bioMérieux's Immunoassay Biomarkers Portfolio by Acquiring Astute 143

Illumina and Bristol-Myers Squibb Collaborate to Develop and Market CDxs for Cancer Drugs 143

Release of Magnetom Sola and BioMatrix Technology by Siemens to Expand Personalized Medicine 143

Siemens Introduces a Novel Acuson Juniper Next-Generation Ultrasound System 144

Metabolon's Meta UDX™ Test is Now Available for Difficult-to-Diagnose Patient Cases 144

Launch of Shimadzu's Nexera Mikros Microflow Liquid Chromatography Mass Spectrometry System 144

Launch of Genedata Profiler® 11.0 Enterprise Software Platform for Omics-based Profiling of Patients 144

Banyan Biomarkers Receives FDA Grant for the Commercialization of the First IVD Blood Test for TBI ... 145

US FDA Approves Myriad's BRACAnalysis CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Metastatic Breast Cancer 145

Myriad Genetics Strengthens Research Collaboration with AstraZeneca 145

NanoString and RikenGenesis to Commercialize nCounter-Based Diagnostic Assays in Japan 145

AMPIPROBE® Women's Health Panel Launched by Enzo Clinical Labs 146

Collaborative NGS Technology Development Deal Signed

by Illumina and KingMed 146

Fast Track Diagnostics Completely Taken Over by Siemens . 146

Siemens Collaborates With Circle Cardiovascular to Improve Cardiac Imaging 146

Epigenomics Receives CE-IVD Mark for Lung Cancer Test Epi proLung® 147

Agendia Collaborates with Bluebee to Launch MammaPrint® BluePrint® Breast Cancer Recurrence and Molecular Subtyping Kit 147

sphingotec and Ortho Jointly Offer sphingotest® bio-ADM® Assay for Clinical Laboratories Globally 147

Agendia and Institute Curie Partners for the Co-validation Study of MammaPrint® BluePrint® Kit 147

sphingotec and Mayo Clinic Partner to Assess Four Biomarkers 148

EKF's Procalcitonin Assay Wins FDA Clearance and Validated for Beckman AU Chemistry Analyzers 148

Genomic Health Develops New Prostate Cancer Tests based on Cleveland Diagnostics' IsoPSA™ Reagent and SIA Technology 148

Release of NextSeq™ 550Dx System by Illumina and Extends the Application of MiSeq™ Dx System 149

Ortho Clinical Diagnostics to Use EKF Diagnostics' Diabetic Ketoacidosis Assay 149

Thermo Fisher Scientific and Blueprint Medicines Ink Deal for Oncology Companion Diagnostic Development 149

Expansion of laboratory Hematology Solutions by Siemens and HORIBA 150

Grant of Patent for Singulex Methods to Digitally Detect Single Molecules of Cardiac Troponin 150

Scientific Collaboration of Caprion Biosciences with the FNK Biomarkers Consortium 150

sphingotec Collaborates with Shuwen for Biomarkers Marketing in China 150

Publication of a New Blood Protein Study for Predictive Tuberculosis Infection Using ProteoCarta™ Biomarker Panel 151

VITEK® MS of bioMérieux Receives FDA Approval for Extended Pathogen Detection 151

US FDA Clearance for Bio-Rad's BioPlex 2200 Syphilis Total & RPR Assay Testing Method 151

Thermo Fisher's Companion Diagnostic Test to Simultaneously Screen for Multiple Non-Small Cell Lung Cancer Therapies Approved by FDA 151

BioFire's FilmArray® Respiratory Panel 2 of bioMérieux Obtains FDA Authorization 152

Extended RAS Panel of Illumina Receives FDA Approval 152

CE Mark for Singulex® First Ultrasensitive Cardiac Troponin Assay Powered by Single Molecule Counting Technology... 152

EKF to Distribute Procalcitonin LiquiColor® Test into Eastern Europe, Middle East and APAC 153

sphingotec and bestbion dx Form Acute Care Biomarkers Marketing Pact 153

Joint collaboration of Metabolon and ADLQ to Set up Metabolomics Platform in Qatar 153

Myriad Genetics and BeiGene to Develop Companion Diagnostics for BeiGene's BGB-290 PARP Inhibitor 153

European Release of VeriSeq™ NIPT Solution by Illumina... 154

BacT/ALERT® VIRTUO Blood Culture System of bioMérieux Gains FDA 510(k) Approval 154

bioMérieux Receives CE Approval for FilmArray® Respiratory Panel 2 plus 154

European CE Mark for Singulex® Sgx Clarity® System 154

Expansion of Clinical Assessment of Singulex Sgx Clarity™ System at European Research Sites 155

New V-PLEX® Assays for Th17 Research Introduced by Meso Scale Discovery 155

VIDAS® B.R.A.H.M.S PCT™ of bioMérieux Receives FDA Approval for Respiratory Infection and Sepsis 155

Metabolon partners with Dian to Establish Discovery HD4™ Platform in China 155

bioMérieux inks Deal with Banyan Biomarkers for Development and Commercialization of Blood- Based Biomarkers for TBI.... 156

Singulex and QIAGEN Partnersfor Companion DiagnosticsDevelopment 156

Commercial Release of Vectra® Polaris™ Pathology Imaging System by PerkinElmer 156

Illumina Signs Integrated Genomics Solutions Deal with Philips 156

5. GLOBAL MARKET OVERVIEW 157

5.1 Global Biomarkers Market Overview by Discovery Technology 158

5.1.1 Global Omics Technologies for Biomarkers Market Overview by Segment 160

5.1.1.1 Omics Technology Segments Market Overview by Global Region 162

5.1.1.1.1 Proteomics 162

5.1.1.1.2 Genomics 164

5.1.1.1.3 Metabolomics 166

5.1.1.1.4 Other Omics Technologies 168

5.1.2 Global Bioimaging Market Overview by Modality 170

5.1.2.1 Bioimaging Modalities Market Overview by Global Region 172

5.1.2.1.1 MRI 172

5.1.2.1.2 CT 174

5.1.2.1.3 Ultrasound 176

5.1.2.1.4 Other Bioimaging Modalities 178

5.1.3 Biomarkers Discovery Technology Market Overview by Global Region 180

5.1.3.1 Omics Technologies 180

5.1.3.2 Bioimaging 182

5.1.3.3 Bioinformatics 184

5.2 Global Biomarkers Market Overview by Therapeutic Area 186

5.2.1 Biomarkers Therapeutic Area Market Overview by Global Region 188

5.2.1.1 Oncology 188

5.2.1.2 Cardiology 190

5.2.1.3 Neurology 192

5.2.1.4 Other Therapeutic Areas 194

PART B: REGIONAL MARKET PERSPECTIVE.. 196

REGIONAL MARKET OVERVIEW 198

6. NORTH AMERICA 198

6.1 North American Biomarkers Market Overview by Geographic Region 199

6.2 North American Biomarkers Market Overview by Discovery Technology 201

6.2.1 North American Omics Technologies Market Overview by Segment 203

6.2.2 North American Bioimaging Market Overview by Modality 205

6.2.3 Biomarkers Discovery Technology Market Overview by NA Region 207

6.2.3.1 Omics Technologies 207

6.2.3.2 Bioimaging 209

6.2.3.3 Bioinformatics 211

6.3 North American Biomarkers Market Overview by Therapeutic Area 213

6.4 Major Market Players 215

Abbott Diagnostics (United States) 215

Agilent Technologies, Inc. (United States) 218

Altheadx, Inc. (United States) 227

Asuragen, Inc. (United States) 228

Banyan Biomarkers, Inc. (United States) 229

Beckman Coulter, Inc. (United States) 230

Bg Medicine, Inc. (United States) 233

Bio-Rad Laboratories, Inc. (United States) 234

Bruker Corporation (United States) 237

Caprion Biosciences, Inc. (Canada) 239

Charles River Laboratories, Inc. (United States) 241

Enzo Biochem, Inc. (United States) 243

Ge Healthcare (United States) 244

Genomic Health, Inc. (United States) 246

Illumina, Inc. (United States) 247

Life Diagnostics, Inc. (United States) 255

Lifesign Llc. (United States) 256

Meso Scale Diagnostics Llc. (United States) 258

Metabolon, Inc. (United States) 260

Milliporesigma (United States) 261

Myriad Genetics, Inc. (United States) 263

Myriad Rbm (United States)	265	Ekf Diagnostics Holdings Plc (United Kingdom)	317	8.2.3.2 Bioimaging	367
Nanostring Technologies, Inc. (United States)	266	Epigenomics Ag (Germany)	320	8.2.3.3 Bioinformatics	369
Nexus Dx (United States)	269	F. Hoffmann-La Roche Ag (Switzerland)	321	8.3 Asia-Pacific Biomarkers Market Overview by	
Perkinelmer, Inc. (United States)	270	Genedata Ag (Switzerland)	324	Therapeutic Area	371
Pharmaceutical Product Development Llc (United States)	272	Janssen Pharmaceutica Nv (Belgium)	325	8.4 Human Metabolome Technologies (Japan) - A	
Shimadzu Scientific Instruments (United States)	273	Koninklijke Philips N.V (The Netherlands)	326	Major Market Player	373
Signosis, Inc. (United States)	274	Pamgene International B.V. (The Netherlands)	327	8.5 Country-wise Analysis of Asia-Pacific Biomarkers	
Singulex, Inc. (United States)	275	Qiagen B.V. (The Netherlands)	328	Market	374
Stagezero Life Sciences, Inc. (Canada)	276	Siemens Healthineers (Germany)	331	8.5.1 China	374
Thermo Fisher Scientific, Inc. (United States)	277			8.5.1.1 Chinese Biomarkers Market Overview by	
Waters Corporation (United States)	279			Discovery Technology	375
6.5 Country-wise Analysis of North American		7.5 Country-wise Analysis of European Biomarkers		8.5.2 Japan	377
Biomarkers Market	281	Market	335	8.5.2.1 Japanese Biomarkers Market Overview by	
6.5.1 The United States	281	7.5.1 Germany	335	Discovery Technology	378
6.5.1.1 United States Biomarkers Market Overview by		7.5.1.1 German Biomarkers Market Overview by		8.5.3 India	380
Discovery Technology	282	Discovery Technology	336	8.5.3.1 Indian Biomarkers Market Overview by	
6.5.2 Canada	284	7.5.2 The United Kingdom	338	Discovery Technology	381
6.5.2.1 Canadian Biomarkers Market Overview by		7.5.2.1 United Kingdom Biomarkers Market Overview		8.5.4 Australia	383
Discovery Technology	285	by Discovery Technology	339	8.5.4.1 Australian Biomarkers Market Overview by	
6.5.3 Mexico	287	7.5.3 France	341	Discovery Technology	384
6.5.3.1 Mexican Biomarkers Market Overview by		7.5.3.1 French Biomarkers Market Overview by		8.5.5 Rest of Asia-Pacific	386
Discovery Technology	288	Discovery Technology	342	8.5.5.1 Rest of Asia-Pacific Biomarkers Market	
7. EUROPE	290	7.5.4 Italy	344	Overview by Discovery Technology	387
7.1 European Biomarkers Market Overview by		7.5.4.1 Italian Biomarkers Market Overview by		9. REST OF WORLD	389
Geographic Region	291	Discovery Technology	345	9.1 Rest of World Biomarkers Market Overview by	
7.2 European Biomarkers Market Overview by		7.5.5 Spain	347	Discovery Technology	390
Discovery Technology	293	7.5.5.1 Spanish Biomarkers Market Overview by		9.1.1 Rest of World Omics Technologies Market	
7.2.1 European Omics Technologies Market Overview		Discovery Technology	348	Overview by Segment	392
by Segment	295	7.5.6 Sweden	350	9.1.2 Rest of World Bioimaging Market Overview by	
7.2.2 European Bioimaging Market Overview by		7.5.6.1 Swedish Biomarkers Market Overview by		Modality	394
Modality	297	Discovery Technology	351	9.2 Rest of World Biomarkers Market Overview by	
7.2.3 Biomarkers Discovery Technology Market		7.5.7 Rest of Europe	353	Therapeutic Area	396
Overview by European Region	299	7.5.7.1 Rest of Europe Biomarkers Market Overview		9.3 Rosetta Genomics (Israel) - A Major Market Player ...	398
7.2.3.1 Omics Technologies	299	by Discovery Technology	354	PART C: GUIDE TO THE INDUSTRY	399
7.2.3.2 Bioimaging	301	8. ASIA-PACIFIC	356	1. NORTH AMERICA	399
7.2.3.3 Bioinformatics	303	8.1 Asia-Pacific Biomarkers Market Overview by		2. EUROPE	404
7.3 European Biomarkers Market Overview by		Geographic Region	357	3. ASIA-PACIFIC	407
Therapeutic Area	305	8.2 Asia-Pacific Biomarkers Market Overview by		4. REST OF WORLD	408
7.4 Major Market Players	307	Discovery Technology	359	PART D: ANNEXURE	409
Agendia Nv (The Netherlands)	307	8.2.1 Asia-Pacific Omics Technologies Market		1. RESEARCH METHODOLOGY	409
Akuru Pharma Ab (Sweden)	308	Overview by Segment	361	2. FEEDBACK	411
Bayer Pharma Ag (Germany)	309	8.2.2 Asia-Pacific Bioimaging Market Overview by			
Biocartis Nv (Belgium)	310	Modality	363		
Biomérieux Sa (France)	312	8.2.3 Biomarkers Discovery Technology Market			
Biosystems International Kft (Hungary)	313	Overview by Asia-Pacific Region	365		
Cisbio Bioassays (France)	314	8.2.3.1 Omics Technologies	365		
Decode Genetics (Iceland)	316				

About Industry Experts

Industry Experts' market research, backed by years of experience and an analytical team dedicated to providing the most optimal business solutions, has been specifically designed to provide a variety of benefits, both current and future. Our leading-edge publications make the life easy for corporate strategists, investors, analysts and researchers, startups, consultants, financial and banking executives, academicians and many more. The company also provides customized research reports to cater the needs of the industry.

Business intelligence provides the critical link between comprehending prevailing market conditions and devising strategies to maximize parameters, such as revenues, profits and return on investment in order to gain market share. The significance of market research can be largely understood through the range of factors that impact businesses. These can comprise market size (current and projected), geographic market reach and demand and supply scenario, to name a few. Our ongoing quest to collect up to date and accurate information by conducting online surveys, personal interviews, taking the opinions of senior level executives will enable us to serve our clients better in every possible aspect.

[More about Industry Experts](#)



Industry Experts, Inc.
14726 Ramona Ave, Suite S2
Chino, CA 91710
Greater Los Angeles
United States
Phone: +1-320-iXPERTS (497-3787)

Email: info@industry-experts.com

India Office
1-7-19/C, Street No. 8, Habsiguda
Hyderabad – 500007
India
Phone: +91-40-4018-1314
Fax: +91-40-2715-7746

Website: <http://industry-experts.com>